第一单位:
VA Medical Center, Experimental Chemotherapy Laboratory, Portland, Oregon, USA.
作者:
Galen P,Miley [1]
;
Sovitj,Pou [1]
;
Rolf,Winter [1]
;
Aaron,Nilsen [1]
;
Yuexin,Li [1]
;
Jane X,Kelly [1]
;
Allison M,Stickles [2]
;
Michael W,Mather [3]
;
Isaac P,Forquer [1]
;
April M,Pershing [3]
;
Karen,White [4]
;
David,Shackleford [4]
;
Jessica,Saunders [4]
;
Gong,Chen [4]
;
Li-Min,Ting [5]
;
Kami,Kim [5]
;
Lev N,Zakharov [6]
;
Cristina,Donini [7]
;
Jeremy N,Burrows [7]
;
Akhil B,Vaidya [8]
;
Susan A,Charman [9]
;
Michael K,Riscoe [10]
作者单位:
VA Medical Center, Experimental Chemotherapy Laboratory, Portland, Oregon, USA.
[1]
Oregon Health & Science University, Department of Molecular Microbiology and Immunology, Portland, Oregon, USA.
[2]
Drexel University College of Medicine, Department of Microbiology and Immunology, Philadelphia, Pennsylvania, USA.
[3]
Monash University, Centre for Drug Candidate Optimization, Parkville, Australia.
[4]
Albert Einstein College of Medicine, Departments of Medicine, Pathology, and Microbiology and Immunology, Bronx, New York, USA.
[5]
CAMCOR, University of Oregon, Eugene, Oregon, USA.
[6]
Medicines for Malaria Venture, Geneva, Switzerland.
[7]
Drexel University College of Medicine, Department of Microbiology and Immunology, Philadelphia, Pennsylvania, USA Akhil.Vaidya@DrexelMed.edu Susan.Charman@monash.edu riscoem@ohsu.edu.
[8]
Monash University, Centre for Drug Candidate Optimization, Parkville, Australia Akhil.Vaidya@DrexelMed.edu Susan.Charman@monash.edu riscoem@ohsu.edu.
[9]
VA Medical Center, Experimental Chemotherapy Laboratory, Portland, Oregon, USA Oregon Health & Science University, Department of Molecular Microbiology and Immunology, Portland, Oregon, USA Akhil.Vaidya@DrexelMed.edu Susan.Charman@monash.edu riscoem@ohsu.edu.
[10]
DOI
10.1128/AAC.01183-15
PMID
26124159
发布时间
2020-08-14